SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half
of all cases of kidney failure requiring replacement therapy. The principal cause of death …

Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular
events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains …

Aims Sodium-glucose co-transporter 2 (SGLT2) were originally developed as kidney-
targeting anti-diabetic drugs. However, due to their beneficial cardiac off-target effects (as …

This comprehensive review covers the historical background, physiology, application in type
2 diabetes, novel uses, cardiovascular benefits, side effects and contraindications of sodium …

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …

The findings of recent clinical trials have shown that sodium-glucose co-transporter 2
(SGLT2) inhibitors produce effects beyond glucose lowering and have demonstrated …

In modern cardiology, sodium‐glucose cotransporter 2 (SGLT2) inhibitors are critical
components of heart failure (HF) treatment algorithms and exert their effects primarily by …

The treatment landscape for patients with established or at high risk for cardiovascular
disease and type 2 diabetes mellitus has entirely changed over the past decade, with the …

ABSTRACT Point-of-Care Ultrasonography (PoCUS) aims to include a fifth pillar
(insonation) in the classical physical examination in order to obtain images to answer …